Clinical Trial Details


Research Study Summary

12 week dose ranging study to evaluate the efficacy and safety of Fluticasone Propionate Spiromax administered twice daily compared with placebo in adolescents and adults with persistent asthma uncontrolled on non-steroidal therapy


12 weeks study requiring 6 morning visits. Subjects should be without inhaled corticosteroids for 6 weeks prior to the screening visit.

Patient Inclustion Criteria:

  • Age: > 12 years old and older
  • General good health
  • Prior asthma diagnosis
  • Current therapy: short acting bronchodilator

Patient Exclusion Criteria:

  • History of life-threatening asthma
  • Asthma exacerbations within 3 months of screening
  • History of glaucoma, cataracts, malignancy, COPD, hepatitis B or C
  • History of allergy to milk protein

To Learn more

CW ID: 180222
Date Last Changed: July 19, 2013

Clinical Trial Snapshot

Both Male and Female
12 and up
Overall Status
12 Weeks
Facility Type


Florina Shawwaf, site director
Florida Center for Allergy and Asthma Research
21150 Biscayne Blvd.
# 408
Aventura, FL 33180
Phone: 305-932-3252
Fax: 305-933-0928

View Map

Research Center Information:

Florida Center for Allergy and Asthma Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.